Otsuka, Lundbeck to collaborate on up to five CNS candidates

In a long-term alliance, Otsuka Pharmaceutical Co. Ltd. (the pharmaceutical division of Otsuka Holdings Co. Ltd.) and H. Lundbeck AS have agreed to trade licenses to their CNS candidates. Initially Lundbeck receives co-development and co-promotion rights to Otsuka’s Phase III compounds aripiprazole depot and OPC34712 in North and Latin America, Europe, Australia, and all other territories except Asia, Turkey, and Egypt (where Otsuka retains rights). For up to an additional three of Lundbeck’s early-stage undisclosed psychiatric disorder (including schizophrenia) agents, Otsuka has the option to co-develop and co-promote after Phase IIb is complete.